# US 2021/0171547 A1 · Methods of preparing cytotoxic benzodiazepine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171547 A1
- Document ID: US20210171547A1
- Status: Published application
- Kind: A1
- Application number: 17/101,942
- Filed: 2020-11-23
- Published: 2021-06-10
- Earliest claimed: 2015-07-21
- Assignees: ImmunoGen, Inc.
- Applicants: Immunogen, Inc.
- Inventors: Baudouin Gérard; Manami Shizuka; Michael Louis Miller; Richard A. Silva
- Web page: https://patentgrep.com/patent/US20210171547A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 35/00: Antineoplastic agents
- C07C 303/28: by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
- C07D 487/04: Ortho-condensed systems
- C07K 5/0804: {and aliphatic}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.

## Claims

### Claim at position 1

1-123. (canceled)

### Claim 124

A method of preparing a compound of formula (15d):
or a salt thereof, said method comprising reacting a sulfonating reagent or an esterification reagent with a compound of formula (14d),
wherein X3 is —Cl; X4 is a sulfonate ester or an activated ester; and R100 is (C1-C3)alkoxy.

### Claim 125 (depends on 124)

The method of claim 124, wherein the sulfonating reagent is methansufonyl anhydride, methanesufonyl chloride, p-toluenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, or trifluoromethanesulfonyl anhydride.

### Claim 126 (depends on 125)

The method of claim 125, wherein the sulfonate ester represented by X4 is mesylate, tosylate, brosylate, or triflate.

### Claim 127 (depends on 126)

The method of claim 126, wherein the sulfonate ester represented by X4 is mesylate.

### Claim 128 (depends on 124)

The method of claim 124, wherein the sulfonate ester is reacted with a compound of formula (14d) in the presence of a non-nucleophilic base.

### Claim 129 (depends on 128)

The method of claim 128, wherein the non-nucleophilic base is triethylamine, imidazole, diisopropylethylamine, pyridine, 2,6-lutidine, dimethylformamide, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), or tetramethylpiperidine.

### Claim at position 8

130-132. (canceled)

### Claim 133

A method of preparing a compound of formula (16d):
or a salt thereof, said method comprising reacting a compound of formula (15d)
with a monomer compound of formula (a1),
wherein X3 is —Cl; X4 is a sulfonate ester or an activated ester; and R100 is (C1-C3)alkoxy.

### Claim 134 (depends on 133)

The method of claim 133, wherein the compound of formula (15d) is reacted with a monomer compound of formula (a1) in the presence of a base.

### Claim 135 (depends on 134)

The method of claim 134, wherein the base is sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, or potassium hydride.

### Claim 136

(canceled)

### Claim 137 (depends on 133)

The method of claim 133, wherein the compound of formula (15d) is reacted with a monomer compound of formula (a1) in the presence of a polar aprotic solvent.

### Claim 138 (depends on 137)

The method of claim 137, wherein the polar aprotic solvent is dimethylacetamide.

### Claim at position 15

139-160. (canceled)

### Claim 161

A method of preparing a compound of formula (17d):
or a salt thereof, said method comprising reacting a compound of formula (15d)
with a monomer compound of formula (d1),
wherein X3 is —Cl; X4 is a sulfonate ester or an activated ester; P3 is H or an amine protecting group; and R100 is (C1-C3)alkoxy.

### Claim 162 (depends on 161)

The method of claim 161, wherein the compound of formula (15d) is reacted with a monomer compound of formula (d1) in the presence of a base.

### Claim 163 (depends on 162)

The method of claim 162, wherein the base is sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, or potassium hydride.

### Claim 164

(canceled)

### Claim 165 (depends on 161)

The method of claim 161, wherein the compound of formula (15d) is reacted with a monomer compound of formula (d1) in the presence of a polar aprotic solvent.

### Claim 166 (depends on 165)

The method of claim 165, wherein the polar aprotic solvent is dimethylacetamide.

### Claim 167 (depends on 161)

The method of claim 161, wherein the compound of formula (15d) is reacted with the monomer compound of formula (d1), wherein P3 is H, to form a compound of formula (17d′):

### Claim 168

(canceled)

### Claim 169 (depends on 161)

The method of claim 161, wherein P3 is an amine protecting group and the method further comprises the step of reacting the compound of formula (17d) with an amine deprotecting reagent to form a compound of formula (17d′):

### Claim 170 (depends on 169)

The method of claim 169, wherein the amine deprotecting reagent is selected from the group consisting of tetra-n-butylammonium fluoride, hydrogen fluoride pyridine, cesium fluoride, piperidine, morpholine, acetic acid, or trifluroacetic acid.

### Claim at position 26

171-204. (canceled)

### Claim 205 (depends on 133)

The method of claim 133,
further comprising the step of reacting the compound of formula of (16d) with a reduced monomer of formula (d1):
to form a compound of formula (18d):
or a pharmaceutically acceptable salt thereof, wherein P3 is H or an amine protecting group.

### Claim at position 28

206-216. (canceled)

### Claim 217 (depends on 133)

The method of claim 133,
further comprising the steps of:
(3) reacting the compound of formula (16d) with an imine reducing agent to form a compound of formula (17d′):
or a salt thereof; and
(4) reacting the compound of formula (17d′) with a monomer of formula (a1):
to form the compound of formula (Id′):

### Claim at position 30

218-230. (canceled)
